Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360616066> ?p ?o ?g. }
- W4360616066 endingPage "184" @default.
- W4360616066 startingPage "172" @default.
- W4360616066 abstract "Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase 3 Study 309/KEYNOTE-775. Health-related quality-of-life (HRQoL) is reported.Patients were randomly assigned to receive LEN+PEMBRO (n = 411; LEN 20 mg/day; PEMBRO 200 mg Q3W) or TPC (n = 416; doxorubicin 60 mg/m2 Q3W or paclitaxel 80 mg/m2 [weekly, 3 weeks on/1 week off]). Impact of treatment on HRQoL assessed by the global health status/quality of life (GHS/QoL) score of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) was a secondary objective; other scales of the Quality-of-Life Questionnaire (QLQ-C30), EORTC QLQ-Endometrial, 24 questions (EORTC QLQ-EN24), and EuroQoL 5 dimensions, 5 levels (EQ-5D-5L) were exploratory objectives. HRQoL was assessed on day 1 of each cycle. Completion/compliance, change from baseline, time to first and definitive deterioration were assessed. No multiplicity adjustments were applied for HRQoL endpoints.The latest timepoint at which the predefined rates of completion (≥60%) and compliance (≥80%) were met was week 12. HRQoL at week 12 between treatment groups was generally similar. Time to first deterioration symptom scales favoured LEN+PEMBRO for QLQ-C30 dyspnoea, and QLQ-EN24 for poor body image, tingling/numbness, and hair loss; and TPC was favoured for QLQ-C30 pain, appetite loss, and diarrhoea, and QLQ-EN24 muscular pain. While the QLQ-C30 physical functional scale favoured TPC, other functional scales were generally similar between arms. Time to definitive deterioration favoured LEN+PEMBRO on most scales.HRQoL data from Study 309/KEYNOTE-775, with previously published efficacy and safety results, indicate that LEN+PEMBRO has an overall favourable benefit/risk profile versus TPC for the treatment of patients with aEC.GOV: NCT03517449." @default.
- W4360616066 created "2023-03-24" @default.
- W4360616066 creator A5002536098 @default.
- W4360616066 creator A5010339370 @default.
- W4360616066 creator A5017377631 @default.
- W4360616066 creator A5019789645 @default.
- W4360616066 creator A5025271372 @default.
- W4360616066 creator A5031523656 @default.
- W4360616066 creator A5033051531 @default.
- W4360616066 creator A5035698039 @default.
- W4360616066 creator A5037590677 @default.
- W4360616066 creator A5058238015 @default.
- W4360616066 creator A5061939825 @default.
- W4360616066 creator A5062529556 @default.
- W4360616066 creator A5064217794 @default.
- W4360616066 creator A5066888430 @default.
- W4360616066 creator A5072305917 @default.
- W4360616066 creator A5073713547 @default.
- W4360616066 creator A5074877517 @default.
- W4360616066 creator A5083659627 @default.
- W4360616066 creator A5090979290 @default.
- W4360616066 date "2023-06-01" @default.
- W4360616066 modified "2023-10-15" @default.
- W4360616066 title "Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice" @default.
- W4360616066 cites W2036387697 @default.
- W4360616066 cites W2047101195 @default.
- W4360616066 cites W2115495766 @default.
- W4360616066 cites W2167571044 @default.
- W4360616066 cites W2192004321 @default.
- W4360616066 cites W2432531102 @default.
- W4360616066 cites W2567938962 @default.
- W4360616066 cites W2587851012 @default.
- W4360616066 cites W2787358630 @default.
- W4360616066 cites W2905726151 @default.
- W4360616066 cites W2906639914 @default.
- W4360616066 cites W2914787208 @default.
- W4360616066 cites W2944152232 @default.
- W4360616066 cites W2996132607 @default.
- W4360616066 cites W3001232216 @default.
- W4360616066 cites W3011919019 @default.
- W4360616066 cites W3093220519 @default.
- W4360616066 cites W3111512677 @default.
- W4360616066 cites W3131063362 @default.
- W4360616066 cites W3165018140 @default.
- W4360616066 cites W3181568504 @default.
- W4360616066 cites W4225283321 @default.
- W4360616066 cites W4226407945 @default.
- W4360616066 doi "https://doi.org/10.1016/j.ejca.2023.03.015" @default.
- W4360616066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37086595" @default.
- W4360616066 hasPublicationYear "2023" @default.
- W4360616066 type Work @default.
- W4360616066 citedByCount "1" @default.
- W4360616066 countsByYear W43606160662023 @default.
- W4360616066 crossrefType "journal-article" @default.
- W4360616066 hasAuthorship W4360616066A5002536098 @default.
- W4360616066 hasAuthorship W4360616066A5010339370 @default.
- W4360616066 hasAuthorship W4360616066A5017377631 @default.
- W4360616066 hasAuthorship W4360616066A5019789645 @default.
- W4360616066 hasAuthorship W4360616066A5025271372 @default.
- W4360616066 hasAuthorship W4360616066A5031523656 @default.
- W4360616066 hasAuthorship W4360616066A5033051531 @default.
- W4360616066 hasAuthorship W4360616066A5035698039 @default.
- W4360616066 hasAuthorship W4360616066A5037590677 @default.
- W4360616066 hasAuthorship W4360616066A5058238015 @default.
- W4360616066 hasAuthorship W4360616066A5061939825 @default.
- W4360616066 hasAuthorship W4360616066A5062529556 @default.
- W4360616066 hasAuthorship W4360616066A5064217794 @default.
- W4360616066 hasAuthorship W4360616066A5066888430 @default.
- W4360616066 hasAuthorship W4360616066A5072305917 @default.
- W4360616066 hasAuthorship W4360616066A5073713547 @default.
- W4360616066 hasAuthorship W4360616066A5074877517 @default.
- W4360616066 hasAuthorship W4360616066A5083659627 @default.
- W4360616066 hasAuthorship W4360616066A5090979290 @default.
- W4360616066 hasBestOaLocation W43606160661 @default.
- W4360616066 hasConcept C121608353 @default.
- W4360616066 hasConcept C126322002 @default.
- W4360616066 hasConcept C159110408 @default.
- W4360616066 hasConcept C1862650 @default.
- W4360616066 hasConcept C197934379 @default.
- W4360616066 hasConcept C2776264508 @default.
- W4360616066 hasConcept C2777088508 @default.
- W4360616066 hasConcept C2777701055 @default.
- W4360616066 hasConcept C2778375690 @default.
- W4360616066 hasConcept C2779761222 @default.
- W4360616066 hasConcept C2779951463 @default.
- W4360616066 hasConcept C2780057760 @default.
- W4360616066 hasConcept C71924100 @default.
- W4360616066 hasConceptScore W4360616066C121608353 @default.
- W4360616066 hasConceptScore W4360616066C126322002 @default.
- W4360616066 hasConceptScore W4360616066C159110408 @default.
- W4360616066 hasConceptScore W4360616066C1862650 @default.
- W4360616066 hasConceptScore W4360616066C197934379 @default.
- W4360616066 hasConceptScore W4360616066C2776264508 @default.
- W4360616066 hasConceptScore W4360616066C2777088508 @default.
- W4360616066 hasConceptScore W4360616066C2777701055 @default.
- W4360616066 hasConceptScore W4360616066C2778375690 @default.
- W4360616066 hasConceptScore W4360616066C2779761222 @default.
- W4360616066 hasConceptScore W4360616066C2779951463 @default.